Monday, October 5, 2015

Newsletter on HCV Drugs

Look at what we have in store for you in the October 2015 Newsletter -

HCV Drugs by Alan Franciscus, Editor-in-Chief

Perused about Achillion's most recent clinical trial results from their PROXY study, data about protection refusals, how far we have come in treating the most hard to treat patients, however how far despite everything we need to go to cure everybody with hepatitis C, medication drug communications and re-treatment issues.

____

HealthWise by Lucinda K. Watchman, RN

In the current month's segment, Lucinda answers some essential post-treatment questions from individuals living with hepatitis C.

____

What the hell Are RAVs? by Alan Franciscus, Editor-in-Chief

On the off chance that you have been dealt with before with an immediate acting antiviral prescription, yet not cured, this brief diagram is an imperative point to get it.

____

Depictions by Alan Franciscus, Editor-in-Chief

Three studies that take a gander at treating individuals with cutting edge liver ailment and re-treatment of individuals who had been beforehand treated with direct-acting antiviral medicines however did not accomplish a cure.

____

What's New? by Alan Franciscus, Editor-in-Chief

We have blended our HBV Website to our HCV Website – figure out additional… . Keep in mind to look at our recently re-planned Facebook and Twitter accounts! Simply go to Facebook and Twitter and sort in 'HCV Advocate'. Tail us and realize all the most recent data about hepatitis C and about what we are do

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.